Effect of Beta-Blockers on Mortality after Myocardial Infarction in Adults with COPD

Published Online: Thursday, January 16, 2014
Follow Pharmacy_Times:
Jennifer Quint, clinical lecturer in epidemiology at the London School of Hygiene and Tropical Medicine, and Liam Smeeth, professor of clinical epidemiology at the London School of Hygiene and Tropical Medicine, discuss their BMJ study of UK COPD patients who have experienced a first myocardial infarction and the impact of beta-blocker therapy on mortality.

Related Articles
The FDA has granted priority review to expand the use of AstraZeneca’s ticagrelor (Brilinta).
A new cardiovascular risk estimator can accurately predict heart disease and stroke risk for anyone in the world aged 40 years or older.
Carmela Avena-Woods, BSPharm, PharmD, CGP, assistant clinical professor of clinical pharmacy practice in the College of Pharmacy and Health Sciences at St. John's University, talks about the importance of individualizing treatment for COPD.
Carmela Avena-Woods, BSPharm, PharmD, CGP, assistant clinical professor of clinical pharmacy practice in the College of Pharmacy and Health Sciences at St. John's University, talks about the burden COPD places on society.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$